Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595528 · ClinicalTrials.gov registry record · Phase 2
A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT02595528: Completed Phase 2 study, sponsored by Allergan.
NCT02595528 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 163 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02595528, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).
Primary Outcome
UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved.
Interventions
- DRUG AGN-199201 ophthalmic solution
- DRUG AGN-190584 ophthalmic solution
- DRUG AGN-190584 vehicle
- DRUG AGN-199201 + AGN-190584 Combination
- DRUG AGN-199201 vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2016-04-29 |
| Est. Completion | 2017-10-18 |
| Phase | Phase 2 |
What the finished NCT02595528 record still lists
NCT02595528 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 5 interventions - of which AGN-199201 ophthalmic solution is the first listed.
NCT02595528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02595528 about?
NCT02595528 is a clinical study titled "A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia". This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).
What is the current status of trial NCT02595528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2016-04-29. Estimated completion is 2017-10-18.
What interventions are being tested in trial NCT02595528?
The interventions under investigation include: AGN-199201 ophthalmic solution (DRUG), AGN-190584 ophthalmic solution (DRUG), AGN-190584 vehicle (DRUG), AGN-199201 + AGN-190584 Combination (DRUG), AGN-199201 vehicle (DRUG).
Who is sponsoring clinical trial NCT02595528?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02595528's enrollment target sits among peer trials
163 418th of 2000 higher than 1,583 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI